Physician profile
Sujan Patel
NPI 1174783633
$12,101.13
in general payments reported to CMS, 2019-2025
17 companies · $37.07 in 2025
The $37.07 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11K · 2020: $374 · 2021: $224 · 2022: $157 · 2023: $273 · 2025: $37.07.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $310.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $309.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Pharmaceuticals, INC. | $10,500.72 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $356.69 | 2019-2023 | Fasenra |
| Genzyme Corporation | $291.87 | 2019-2023 | |
| Regeneron Healthcare Solutions, INC. | $243.77 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $229.17 | 2019-2023 | |
| Alk-Abello, INC | $134.85 | 2019-2021 | |
| Optinose US, INC. | $73.20 | 2019-2020 | |
| Glaxosmithkline, LLC. | $56.74 | 2020-2023 | Trelegy Ellipta |
| Merck Sharp & Dohme LLC | $40.42 | 2021-2025 | Welireg, Keytruda |
| Takeda Pharmaceuticals U.S.A., INC. | $33.20 | 2020 | |
| Lilly USA, LLC | $25.00 | 2023 | Jardiance, Baqsimi |
| Shire North American Group INC | $24.82 | 2019 | |
| Gilead Sciences, INC. | $20.20 | 2023 | Veklury |
| Phadia US INC. | $18.80 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.49 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $16.65 | 2025 | Ultomiris |
| Boston Scientific Corporation | $16.54 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sujan Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.